

# Pnina Fishman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2222932/publications.pdf>

Version: 2024-02-01

47  
papers

2,656  
citations

218381

26  
h-index

276539

41  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2238  
citing authors

#	ARTICLE	IF	CITATIONS
1	The A3 Adenosine Receptor Is Highly Expressed in Tumor versus Normal Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4472-4479.	3.2	420
2	Pharmacological and therapeutic effects of A3 adenosine receptor agonists. <i>Drug Discovery Today</i> , 2012, 17, 359-366.	3.2	193
3	A3 adenosine receptor as a target for cancer therapy. <i>Anti-Cancer Drugs</i> , 2002, 13, 437-443.	0.7	114
4	The A3 Adenosine Receptor as a New Target for Cancer Therapy and Chemoprotection. <i>Experimental Cell Research</i> , 2001, 269, 230-236.	1.2	108
5	Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor. <i>Journal of Cellular Physiology</i> , 2001, 186, 19-23.	2.0	108
6	Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. <i>Journal of Rheumatology</i> , 2008, 35, 41-8.	1.0	106
7	Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. <i>Oncogene</i> , 2002, 21, 4060-4064.	2.6	97
8	An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 $\beta$ and NF- $\kappa$ B. <i>Oncogene</i> , 2004, 23, 2465-2471.	2.6	93
9	A3 Adenosine Receptor Activation in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 42121-42130.	1.6	91
10	Pharmacology and Therapeutic Applications of A3 Receptor Subtype. <i>Current Topics in Medicinal Chemistry</i> , 2003, 3, 463-469.	1.0	84
11	The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. <i>Arthritis Research and Therapy</i> , 2006, 8, R33.	1.6	80
12	The anti-inflammatory effect of A <sub>3</sub> adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1601-1613.	1.9	79
13	Treatment of Dry Eye Syndrome with Orally Administered CF101. <i>Ophthalmology</i> , 2010, 117, 1287-1293.	2.5	78
14	CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. <i>Oncologist</i> , 2013, 18, 25-26.	1.9	78
15	Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. <i>Journal of Rheumatology</i> , 2005, 32, 469-76.	1.0	72
16	Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. <i>Anticancer Research</i> , 2003, 23, 2077-83.	0.5	70
17	Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. <i>Journal of Rheumatology</i> , 2007, 34, 20-6.	1.0	68
18	Autoantibodies to tyrosinase. , 1997, 79, 1461-1464.		60

#	ARTICLE	IF	CITATIONS
19	Adenosine acts as a chemoprotective agent by stimulating G-CSF production: A role for A1 and A3 adenosine receptors. <i>Journal of Cellular Physiology</i> , 2000, 183, 393-398.	2.0	55
20	The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2359-2362.	1.0	54
21	Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus. <i>Oncogene</i> , 2001, 20, 4864-4870.	2.6	53
22	Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. <i>Arthritis Research and Therapy</i> , 2006, 8, R169.	1.6	48
23	Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. <i>International Journal of Molecular Medicine</i> , 2011, 28, 727-31.	1.8	44
24	CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model. <i>Neoplasia</i> , 2005, 7, 85-90.	2.3	40
25	Aspirin-Interleukin-3 Interrelationships in Patients With Anti-Phospholipid Syndrome. <i>American Journal of Reproductive Immunology</i> , 1996, 35, 80-84.	1.2	34
26	Targeting the A <sub>3</sub> adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 491-497.	2.0	28
27	Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 931-8.	0.4	28
28	A3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	1.4	27
29	Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A <sub>3</sub> Adenosine Receptor Agonist Piclidenoson. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	25
30	Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial. <i>Cancers</i> , 2021, 13, 187.	1.7	25
31	The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2256-2264.	1.8	25
32	A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. <i>Molecular Medicine Reports</i> , 2016, 14, 4335-4341.	1.1	24
33	Targeting the A3 adenosine receptor for glaucoma treatment (Review). <i>Molecular Medicine Reports</i> , 2013, 7, 1723-1725.	1.1	23
34	Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1405-1415.	1.9	19
35	Modulation of the A3 adenosine receptor by low agonist concentration induces antitumor and myelostimulatory effects. <i>Drug Development Research</i> , 2003, 58, 386-389.	1.4	18
36	Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data. <i>Molecules</i> , 2022, 27, 3680.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Reactivity to tyrosinase: Expression in cancer (melanoma) and autoimmunity (vitiligo). Human Antibodies, 1996, 7, 151-156.	0.6	16
38	IVIg to prevent tumor metastases (Review). International Journal of Oncology, 2002, 21, 875-80.	1.4	11
39	Chloramphenicol Induced Inhibition of Platelet Protein Synthesis: <i>in Vitro</i> and <i>in Vivo</i> Studies. British Journal of Haematology, 1976, 33, 53-59.	1.2	9
40	Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clinical and Experimental Metastasis, 1999, 17, 531-535.	1.7	9
41	Adenosine Receptors and Current Opportunities to Treat Cancer. , 2018, , 543-555.		7
42	Suppression of experimental zymosan-induced arthritis by intraperitoneal administration of adenosine. Drug Development Research, 2002, 57, 182-186.	1.4	6
43	Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. , 2010, , 291-298.		3
44	Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. , 2010, , 301-317.		3
45	<scp>A3</scp> adenosine receptor allosteric modulator <scp>CF602</scp> reverses erectile dysfunction in a diabetic rat model. Andrologia, 2022, 54, .	1.0	3
46	Autoantibodies to tyrosinase. , 1997, 79, 1461.		2
47	Editorial: targeting aberrant hepatic inflammation for treatment of nonâ€œalcoholic steatohepatitisâ€œ authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 485-486.	1.9	0